title: [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
abstract: BACKGROUND
  A clinical trial of Docetaxel was performed by tri-weekly administration in patients with advanced or recurrent breast cancer. However, careful observation is necessary for outpatients because serious neutropenia often occurs during the therapy. A bi-weekly schedule is recommended since weekly administration requires more visits to the hospital. Docetaxel is proved to express synergistic efficacy in combination with 5'-DFUR by induced dThdPase in vivo. But there are no clinical trials to evaluate efficacy of bi-weekly Docetaxel and 5'-DFUR combination therapy.
  
  
  OBJECTIVE
  To evaluate safety, the recommended dose of Docetaxel and the efficacy of biweekly Docetaxel and 5'-DFUR combination therapy.
  
  
  METHODS
  Patients with advanced or recurrent breast cancer within 1 regimen of prior chemotherapy and without prior use of both Docetaxel and 5'-DFUR were enrolled. 5'-DFUR was orally administered by 600 mg/day. Docetaxel was intravenously given for at least 2 cycles (8 weeks) by 30 mg/m(2) for level 1, 40 mg/m(2) for level 2 and 50 mg/m(2) for level 3. At each level with 3 cases enrolled,the maximum tolerated dose (MTD) level was defined as that in which 2 or 3 cases showed dose limiting toxicity (DLT). The recommended dose was defined as the dose before MTD level. Therapeutic safety was evaluated by analyses of adverse events with the recommended dose.
  
  
  RESULTS
  MTD was in level 3 and the recommended dose of Docetaxel was 40 mg/m(2) of level 2. No DLT was observed in level 2, and this combination therapy seemed safe and feasible for outpatients. In addition, all 6 cases for whom therapeutic efficacy was evaluated expressed a clinical response.
authors.affiliation: Dept. of Breast and Thyroid Surgery, Kawasaki Medical School.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonoo
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Tanaka
authors.forename: Junichi
authors.initials: J
authors.lastname: Kurebayashi
authors.forename: Tadaoki
authors.initials: T
authors.lastname: Morimoto
authors.forename: Akira
authors.initials: A
authors.lastname: Tangoku
authors.forename: Kansei
authors.initials: K
authors.lastname: Komaki
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kataoka
authors.forename: Kiyosuke
authors.initials: K
authors.lastname: Ishiguro
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshizawa
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D005467:Floxuridine; D000077143:Docetaxel; C025034:doxifluridine